LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and profitability as the company expands in PAH.
LQDA, FLXS and AGX screen as low-beta stocks with positive price moves, solid trading volume and company-specific growth drivers amid market fears.
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Fragile Iran ceasefire keeps stocks volatile. Low-beta picks LQDA, CVX, OXY and VLO show recent gains and solid volume.
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Middle East tensions are stoking volatility; a low-beta screen spotlights Liquidia, Exxon Mobil, Valero Energy and Diamondback Energy.
Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript